Pathologic complete remission after neoadjuvant chemotherapy has a role in guiding the management of breast cancer. The present meta-analysis examined the accuracy of contrast-enhanced magnetic resonance imaging (CE-MRI) and diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting the response to neoadjuvant chemotherapy and compared CE-MRI with ultrasonography, mammography, and positron emission tomography/ computed tomography (PET/CT). Medical subject heading terms and related keywords were searched to generate a compilation of eligible studies. The pooled sensitivity, specificity, diagnostic odds ratio, area under summary receiver operating characteristic curve (AUC), and Youden index (Q* index) were used to estimate the diagnostic efficacy of CE-MRI, DW-MRI, ultrasonography, mammography, and PET/CT. A total of 54 studies of CE-MRI and 8 studies of DW-MRI were included. The overall AUC and the Q* index values for CE-MRI and DW-MRI were 0.88 and 0.94 and 0.80 and 0.85, respectively. According to the summary receiver operating characteristic curves, CE-MRI resulted in a higher AUC value and Q* index compared with ultrasonography and mammography but had values similar to those of DW-MRI and PET/CT. CE-MRI accurately assessed pathologic complete remission in specificity, and PET/CT and DW-MRI accurately assessed pathologic complete remission in sensitivity. The present meta-analysis indicates that CE-MRI has high specificity and DW-MRI has high sensitivity in predicting pathologic complete remission after neoadjuvant chemotherapy. CE-MRI is more accurate than ultrasonography or mammography. Additionally, PET/CT is valuable for predicting pathologic complete remission. CE-MRI, combined with PET/CT or DW-MRI, might allow for a more precise assessment of pathologic complete remission.
Introduction
Neoadjuvant chemotherapy (NAC), also called termed or primary chemotherapy, was first described in patients with locally advanced breast cancer in 1978. 1 It plays a well-established role in the management of breast cancer. 2 One of the advantages of NAC is to downstage the primary tumor and increase the likelihood of successful breast-conserving surgery, avoiding mastectomy. 3 Published clinical trials have shown that breast cancer patients with pathologic complete remission (pCR) after NAC have a significantly better prognosis than those without pCR. [4] [5] [6] [7] [8] [9] The accurate assessment of the response to NAC before surgery is crucial in breast cancer management. If pCR cases could be distinguished perfectly from non-pCR cases, additional surgical management would be avoided. Ultrasonography, mammography, and contrast-enhanced magnetic resonance imaging (CE-MRI) have been widely applied to evaluate and predict the pathologic response in patients with breast cancer who received NAC. However, positron emission tomography/computed tomography (PET/CT) has not been widely used. [10] [11] [12] CE-MRI has been proposed to be valuable in predicting the responsiveness of breast cancer after NAC. 13 Also, diffusionweighted MRI (DW-MRI) has been considered a potential tool to predict the response to chemotherapy. 14, 15 Therefore, we focused on the performance of MRI (including CE-MRI and DW-MRI) in predicting for pCR after NAC. Despite the value of CE-MRI in detecting the response to NAC, the routine use of CE-MRI remains controversial because of the cost, lengthy imaging time, use of contrast injection, and relatively low sensitivity in detecting pCR. 16 Skaane et al 17 reported that ultrasonography and mammography were the primary tools for evaluating the response to NAC; however, the accuracy was limited. Most published studies have evaluated MRI and other imaging techniques in isolation, not in the same cohort. In the present study, we examined the evidence of the accuracy of CE-MRI compared with mammography, ultrasonography, and PET/CT in identifying the response to NAC. Londero et al 18 and Rosen et al 19 showed that 
Materials and Methods

Published Data Search and Review
We systematically searched the published data in PubMed, Ovid, Cochrane Library (from the beginning of 1992 to April 1, 2016). The search terms were selected to link MRI with breast cancer and the response to NAC, using "response," "magnetic resonance imaging OR MR," and "neoadjuvant OR preoperative OR pre-surgery OR primary chemotherapy" AND "breast cancer OR breast tumor OR breast neoplasm OR mammary cancer" as subject heading terms and keywords. All abstracts were screened for eligibility by 1 reviewer, and a 10% sample was assessed independently by a second reviewer to ensure consistent application of the eligibility criteria.
Eligibility Criteria
The inclusion criteria were as follows: (1) patients with newly diagnosed breast cancer who had undergone MRI examination after complete NAC; (2) studies of ! 20 patients; and (3) studies providing sufficient data, either directly or indirectly through a 2 Â 2 table (the numbers of true-positive, true-negative, false-positive, and false-negative findings) to enable calculation of point estimates and 95% confidence intervals (CIs) for the operating characteristics of MRI compared with the reference standard (pathologic response determined by surgical excision). Studies in which patients were treated with concurrent chemotherapy and radiotherapy were excluded. Also, studies not reported in the 
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English language were excluded. In addition, studies in which MRI was undertaken only during NAC were ineligible. Finally, studies of different diagnostic methods that were presented in combination and could not be separated were excluded.
Data Extraction
For each eligible study, we extracted the following information: first author, number of patients, mean age, clinical characteristics, therapeutic interventions, reference standard, and number of responses and nonresponses. True-positive, false-positive, falsenegative, and true-negative values were obtained from the MRI scans and other assessment methods (ultrasonography, mammography, and PET/CT) after a comparison with the pathologic results.
Data Synthesis and Statistical Analysis
For each study, we constructed a 2 Â 2 contingency table in which all participants were classified as having positive or negative imaging results and pCR or not after NAC. All analyses were performed using Stata, version 13.0 (StataCorp LP) and MetaDiSc. 23 The heterogeneity among the different studies was analyzed using a c 2 test and assessed by forest plot, with Q and I 2 statistics presented. If heterogeneity was present, defined as I 2 > 50%, the random effects model was selected. Otherwise, the fixed effects model was selected. The threshold effect was an important source of heterogeneity. To judge whether the threshold effect was present, Spearman correlation coefficients (between the logit of sensitivity and logit of specificity) were calculated. A P value for Spearman correlation coefficients of < .05 indicated that threshold effects were present among the studies.
To further assess for possible explanations for the heterogeneity of a nonthreshold effect, we applied single-factor meta-regression analysis by the pCR definition, pCR rate (2 studies 24, 25 reported that the mean pCR rate was approximately 17%; thus, we chose 17% as the cutoff value), study population era (midpoint of study population enrollment, 2005), dosage of gadolinium-based materials, and whether to accept blind subjects. The pooled diagnostic odds ratio was calculated, which expresses how much greater the odds of having a pCR is for those with a positive test result compared with a negative test result. The area under the summary receiver operating characteristic curve (AUC) is an index to evaluate a diagnostic test and summarizes the diagnostic performance as a single number. A perfect test will have an AUC close to 1 and a poor test will have an AUC close to 0.5. The Youden index (Q* index) is another useful statistic and is defined by the point at which sensitivity and specificity are equal, closest to the ideal top-left corner of the receiver operating characteristic space. Deek's funnel plot was used to evaluate for publication bias. An asymmetric Deek's funnel plot would suggest that a publication bias is present.
Results
Study Selection
A systematic search yielded a total of 1560 studies from the PubMed, Ovid, and Cochrane Library databases; 659 duplicate studies were excluded. After reviewing the titles and abstracts, 302 studies were considered as potential candidates for inclusion. After an in-depth reading, 191 studies were excluded, because they did not meet our eligibility criteria. Of the remaining 111 eligible studies, 8 studies lacked raw data, 33 studies had not presented sufficient data to construct or calculate the TP, FP, FN, and TN values, and 11 studies had included < 20 patients. Two studies 26, 27 were excluded because of repetitive data (investigators with additional studies 28, 29 5811 cases with MRI data available were included in our present meta-analysis. A flowchart of the published data search is presented in Figure 1 . Figure 2 .
Study Description and Patient Characteristics
Accuracy of MRI
The pooled sensitivity of CE-MRI across the studies was 0.64 (95% confidence interval [CI], 0.56-0.70), and the pooled specificity was 0.92 (95% CI, 0.89-0.94). The AUC for CE-MRI across all 54 studies was 0.88 (95% CI, 0.85-0.91). The Q* index was 0.81 ( Figures 3 and 4) . The subgroup analysis of different definitions of pCR is shown in Figure 2 . Differences in the pooled sensitivity, specificity, and AUC of the different subgroups were not statistically significant.
The pooled sensitivity of DW-MRI across the studies was 0.93 (95% CI, 0.53-0.99), and the pooled specificity was 0.85 (95% CI, 0.68-0.94). The AUC for DW-MRI across all 8 studies was 0.94 (95% CI, 0.91-0.95). The Q* index was 0.85 ( Figures 5 and 6 ).
Comparisons of Accuracy of MRI and Other Tests
The results of the comparisons between CE-MRI and ultrasonography based on the subgroups from 10 studies 21, 39, 40, 44, 49, 55, 60, 69, 70, 73 in the same cohort of patients are listed in Table 2 . CE-MRI and mammography were compared in 4 studies. 40, 49, 55, 73 CE-MRI and PET/CT were compared in 3 studies. 21, 49, 54 CE-MRI and DW-MRI were compared in 5 studies. 51, 53, 63, 64, 76 Evidence showed that CE-MRI had greater accuracy than ultrasonography and mammography (the AUC 95% CIs did not overlap). Differences between CE-MRI and PET/CT or DW-MRI were not observed. However, the results indicated that PET/CT or DW-MRI had a high sensitivity and CE-MRI, a high specificity. Details are listed in Table 3 .
Heterogeneity Test
The present study confirmed that heterogeneity existed in both CE-MRI (I 2 > 50%; P < .1) and DW-MRI (I 2 > 50%; P < .1)
groups. The Spearman correlation coefficients for CE-MRI and DW-MRI were 0.426 (P ¼ .002 and P < .05) and 0.750 (P ¼ .052 and P > .05), respectively. These results reflect a threshold effect in 
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Clinical Breast Cancer July 2017 -251 the CE-MRI group but no threshold effect in the DW-MRI group. In the CE-MRI group, a single-factor meta-regression analysis was conducted to evaluate the nonthreshold effect; the coefficients and P values are listed in Table 2 . The meta-regression analysis showed that no statistically significant differences were present among the subgroups. In the DW-MRI group, meta-regression analysis was not performed, because the sample size was too small (only 8 studies were included). A sensitivity analysis was conducted, and the heterogeneity did not decrease significantly.
The publication bias for both CE-MRI (P ¼ .14) and DW-MRI (P ¼ .65) was insignificant. The Deek funnel plot for both was symmetrical. These results indicate that the publication bias was not statistically significant.
Discussion
In the present systematic review, we aimed to estimate the accuracy of CE-MRI and DW-MRI to predict pCR after NAC in patients with breast cancer using available data. The studies compared the accuracy of CE-MRI and DW-MRI against that of pathologic results as the reference standard. We found that CE-MRI had a high specificity (correct detection of residual tumor) and relatively low sensitivity in detecting pCR. The low sensitivity might have resulted from the following reasons: reactive inflammation caused by tumor response and healing, surrounding sclerosis and necrosis, perilesional edema, multiple scattered lesions, and the presence of accompanying DCIS. 28, 79, 80 The sensitivity (0.93)
showed that DW-MRI is also an excellent tool for detecting pCR. However, the sample size was small, with only 8 studies available. This result suggests that DW-MRI is a potentially valuable tool with a wide use for detecting pCR. Because the pCR was not defined uniformly across the studies, the CE-MRI accuracy was independently assessed within groups with similar pCR definitions. In the subgroup that defined pCR as the complete disappearance of invasive carcinoma and DCIS, the Q* index was 0.81 and the AUC was 0.88 (95% CI, 0.85-0.91). In the subgroup that defined pCR as the absence of invasive cancer, the Q* index was 0.80 and the AUC was 0.87 (95% CI, 0.83-0.89). No statistically significant differences were found between the subgroups that defined pCR differently.
Several studies have compared CE-MRI with other imaging tools in assessing the response of breast cancer to NAC among different cohorts of patients in 2 separate modalities. In the present analysis, we systematically compared the sensitivity, specificity, Q* index, and AUC for different imaging techniques in the same cohort of patients who had received NAC. CE-MRI had a greater overall AUC and Q* index compared with ultrasonography or mammography. This result suggests that PET/CT and DW-MRI might have AUC and Q* index values similar to those of CE-MRI. In our comparison, we found that DW-MRI and PET/CT had high sensitivity and CE-MRI had high specificity in predicting pCR to NAC in breast cancer patients. the present analysis not only added additional studies, but also examined the accuracy of DW-MRI and PET/CT compared with CE-MRI. We also excluded studies that had examined concurrent chemotherapy and radiotherapy, which were included in the analysis by Marinovich et al. 81 Marinovich et al 81 found no difference in accuracy between CE-MRI and ultrasonography. However, CE-MRI was superior to ultrasonography in our analysis. The pooled sensitivity and specificity was 64% and 92%, respectively, similar to the findings from Yuan et al. 82 Another meta-analysis study compared the accuracy of MRI and PET/CT in predicting pCR 83 ; however, MRI and PET/ CT were performed during, not after, NAC. In our analysis, all eligible studies must have performed MRI after NAC completion. The present analysis had some limitations. The major limitation of our analysis was that the studies we examined were not prospectively designed to evaluate MRI accuracy. Therefore, not all patients in the study data had been treated with the same standard, which accounted for the heterogeneity among the studies. The threshold effects were the significant factors resulting in heterogeneity among these studies. The criteria used to access the complete response to NAC by MRI were not standardized. Second, the studies that compared PET/CT and DW-MRI with CE-MRI in same cohort of patients were limited. Third, the breast cancer subtype and treatment regimens can influence CE-MRI accuracy. 84 Investigating the accuracy of responses in different molecular subtypes would allow us to draw more powerful conclusions. Most studies included various disease subtypes and the data were combined, making it difficult to tease apart the contributions from the particular subtypes. Therefore, we were limited in discussing the NAC response accuracy in different molecular subtypes in detail, which could be addressed in the future. Among the studies included in our analysis, we did not find a significant statistical publication bias. However, it is important to note that this finding might have been influenced by studies that were excluded from our analysis.
Conclusion
We cannot accurately predict whether pCR is achieved until the final breast surgery has been performed, and this will always influence whether chemotherapy and surgery are deficient or excessive beforehand. In the present analysis, we found that CE-MRI had a high specificity and DW-MRI a high sensitivity in assessing the pCR. CE-MRI is more accurate than ultrasonography or mammography. Additionally, PET/CT is valuable for predicting pCR. PET/CT and DW-MRI monitoring reduced the incidence of overestimation using CE-MRI of the treatment response. Thus, PET/CT, DW-MRI, and CE-MRI could play different roles in 
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Clinical Breast Cancer July 2017 -253 monitoring the response to NAC. Therefore, the combined use of CE-MRI with PET/CT or DW-MRI might yield greater precision in assessing pCR. Additional well-designed clinical trials are required to further investigate this conclusion. 
